Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Researchers recommend performing echocardiography at rest and during exercise to screen for pulmonary arterial hypertension in patients with systemic sclerosis.
Oral treatments for pulmonary arterial hypertension reduce patients’ risk of clinical worsening but have little effect on survival, say the authors of a meta-analysis.
Analysis of the REVEAL registry shows poor 5-year outcomes for patients with pulmonary arterial hypertension, despite improvements due to targeted therapies.
Pulmonary arterial hypertension is often not diagnosed in adult patients with congenital heart disease until 6 years or more after their symptoms first appear, research shows.
Mayo Clinic in Jacksonville, Fla., and United Therapeutics Corporation today announced a collaboration to build and operate a lung restoration center on the Mayo campus. The goal is to significantly increase the volume of lungs for transplantation by preserving and restoring selected marginal donor lungs, making them viable for transplantation. The restored lungs will be made available to patients at Mayo Clinic and other transplant centers throughout the United States.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.
Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim) studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.
Research shows that a risk score based on noninvasive measures can identify left heart failure in a “substantial percentage” of patients with suspected pulmonary arterial hypertension, reducing the need for right heart catheterisation.
Patients with pulmonary arterial hypertension achieve greater improvements in right heart haemodynamics if epoprostenol is given rapidly and at a high dose, research suggests.
A meta-analysis supports the efficacy of ambrisentan in patients with pulmonary arterial hypertension.
Ascendis Pharma A/S, a clinical stage biotechnology company that applies its TransCon technology to address significant unmet medical needs, announced today that its Phase 1 single ascending dose study of TransCon Treprostinil produced dose-dependent increases in plasma treprostinil levels in-line with expectations.
A study has found that treatment of pulmonary arterial hypertension in patients younger than 55 years significantly improves their performance on the 6-minute walk test.
Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension.
Capillary pCO2 can be used to distinguish idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction, research indicates.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.
Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.
Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH).
Researchers have provided evidence for distinct processes underlying vasodilator-responsive and nonresponsive idiopathic pulmonary arterial hypertension.
An enzyme that facilitates modification of proteins via a glucose metabolism pathway may promote cell proliferation in the lung tissue of patients with idiopathic pulmonary arterial hypertension, say researchers.